VANCOUVER, BC--(Marketwired - Feb 1, 2016) - Breathtec Biomedical Inc. (CNSX: BTH) (CSE: BTH) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of life threatening diseases, is pleased to announce that the Company expects to start trading on the Canadian Securities Exchange (the “Exchange”) on Monday, February 1, 2016 under the symbol “BTH”.
Breathtec will be focusing its efforts to develop hand held breath testing and analysis tools for the early detection of infections, diabetes, and certain types of cancer.
“A disruptive technology is an innovation that eventually overturns the status quo and forever changes the future. Breathtec is aiming to change the world of medical diagnostics with the development of hand held breath testing devices that will change the way doctors detect diseases,” said Kal Malhi, President of Breathtec. “Breathtec has a very strong partnership with the University of Florida and is also currently evaluating several other breath testing technologies from around the world to add to our intellectual property portfolio. We are excited to begin trading as a public company in Canada.”
To date the Company has raised CAD $3.4 million that will be utilized to develop breath analysis diagnostic devices and pursue similar technologies.
Capital Markets Advisory
In related news, Breathtec is pleased to announce that it has retained Core Capital Partners to provide capital markets advisory. Core Capital provides capital raising, advisory and deal structure advice to emerging Health Care and Technology companies. Core specializes in funding early stage, high-growth ideas via a public equity approach. Core has an unmatched access to capital, ability to identify opportunities and accelerate transactions and corporate developments.
Under the terms of the agreement, with an effective date of February 1, 2016, Core Capital will receive compensation of $5,000 per month. Subject to approval from the Canadian Securities Exchange (“CSE”) Core Capital will also receive 400,000 options exercisable at a price of $0.25 per share until February 1, 2021.
ON BEHALF OF THE BOARD
“Kal Malhi”
President & Director